Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations

Abstract

The t(4;14)(p16.3;q32) chromosomal translocation occurs in approximately 20% of multiple myelomas (MM) and leads to the apparent deregulation of two genes located on 4p16.3: the fibroblast growth factor receptor 3 (FGFR3) and the putative transcription factor WHSC1/MMSET. Interestingly, FGFR3 mutations known to be associated with autosomal dominant human skeletal disorders have also been found in some MM cell lines with t(4;14) but their pathogenetic role in MM is still controversial. Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line. All of the cell lines present a heterozygous FGFR3 gene mutation and transcribe the mutated allele; unlike KMS-11 and OPM-2 (which express the IIIc isoform), the KMS-18 cell line expresses prevalently the isoform IIIb. We demonstrated that, under serum-starved conditions, KMS-11 and OPM-2 cells express appreciable levels of phosphorylated FGFR3 mutants indicating a constitutive activation of the Y373C and K650E receptors; the addition of the aFGF ligand further increased the level of receptor phosphorylation. Conversely, the FGFR3 mutant in KMS-18 does not seem to be constitutively activated since it was phosphorylated only in the presence of the ligand. In all three MM cell lines, ligand-stimulated FGFR3 mutants activated the MAP kinase signaling pathway but did not apparently involve either the STAT1 or STAT3 cascades. However, when transfected in 293T cells, G384D, like Y373C and K650E, was capable of activating MAPK, STAT1 and STAT3 under serum-starved condition. Finally, a focus formation assay of NIH3T3 cells transfected with FGFR3-expressing plasmid vectors showed that Y373C and K650E (albeit at different levels) but not G384D or the wild-type receptor, can induce transformed foci. Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Basilico C, Moscatelli D . 1992 Adv. Cancer Res. 59: 115–165

  • Cappellen D, De Oliveira C, Ricol D, de Medina SGD, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyl F . 1999 Nature Genet. 23: 18–19

  • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R . 1999 Immunity 16: 2647–2656

  • Chen C, Okayama H . 1987 Mol. Cell. Biol. 7: 2745–2752

  • Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuel WM, Bergsagel PL . 1997 Nature Genet. 16: 260–264

  • Chesi M, Nardini E, Lim RSC, Smith KD, Kuel WM, Bergsagel PL . 1998 Blood 92: 3025–3034

  • d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ . 1998 Cell Growth Diff. 9: 71–78

  • Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P . 1996 Cell 84: 911–921

  • Finelli P, Fabris S, Zagano S, Baldini L, Intini D, Nobili L, Lombardi L, Maiolo AT, Neri A . 1999 Blood 94: 724–732

  • Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A . 1998 Blood 15: 2987–2989 letter

  • Francomano CA . 1996 Am. J. Hum. Genet. 59: A25

  • Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Pierotti MA . 1995 Mol. Cell. Biol. 15: 6118–6127

  • Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ . 2000 Oncogene 19: 3309–3320

  • Johnson DE, Williams LT . 1993 Adv. Cancer Res. 60: 12–41

  • Johnson MR, Valentine C, Basilico C, Mansukhani A . 1998 Oncogene 16: 2647–2656

  • Johnston CL, Cox HC, Gomm JJ, Coombes RC . 1995 J. Biol. Chem. 270: 30643–30650

  • Kanai M, Goke M, Tsunekawa S, Podolsky DK . 1997 J. Biol. Chem. 272: 6621–6628

  • Kannan K, Givol D . 2000 Life 49: 197–205

  • Keegan K, Johnson DE, Williams LT, Hayman M . 1991 Proc. Nat. Acad. Sci. 88: 1095–1099

  • Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J . 1998 J. Biol. Chem. 273: 13007–13014

  • Li Y, Mangasarian K, Mansukhani A, Basilico C . 1997 Oncogene 14: 1397–1406

  • Li ZH, Plowright EE, Hawley TS, Bergsagel PL, Chesi M, Hawley RG, Stewart AK . 1998 Blood 92: (suppl.1) A1582

  • Lofts FJ, Hurst HC, Sternberg MJE, Gullick WJ . 1993 Oncogene 8: 2813–2820

  • Lombardi L, Newcomb EW, Dalla-Favera R . 1987 Cell 49: 161–170

  • Malgeri U, Baldini L, Perfetti V, Fabris S, Colli Vignarelli M, Colombo G, Lotti V, Compasso S, Bogni S, Lombardi L, Maiolo AT, Neri A . 2000 Cancer Res. 60: 4058–4061

  • Muenke M, Schell U . 1997 TIG 11: 308–313

  • Murgue B, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK . 1994 Cancer Res. 54: 5206–5211

  • Namba M, Ohtsuki T, Mori M, Togawa A, Wada H, Sugihara T, Yawata Y, Kimoto T . 1989 In Vitro Cell. Devel. Biol. 25: 723–729

  • Naski M, Wang Q, Xu J, Ornitz DM . 1996 Nature Genet. 13: 233–237

  • Otsuki T, Nakazawa N, Taniwaki M, Yamada O, Sakaguchi H, Wada H, Yawata Y, Ueki A . 1998 Int. J. Oncol. 12: 545–552

  • Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK . 2000 Blood 95: 992–998

  • Raffioni S, Zhu YZ, Bradshaw RA, Thompson LM . 1998 J. Biol. Chem. 273: 35250–35259

  • Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi L, Maiolo AT, Neri A . 1997 Blood 90: 4062–4070

  • Ronchetti D, Bogni S, Finelli P, Lombardi L, Otsuki T, Maiolo AT, Neri A . 2001 Leukemia in press

  • Rousseau F, Ghouzzi VE, Delezoide AL, Mallet LL, Le Merrer M, Munnich A, Bonaventure J . 1996 Hum. Mol. Genet. 5: 509–512

  • Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C . 1999 Genes Dev. 13: 1361–1366

  • Sambrook J, Fritch EF, Maniatis T . 1989 Molecular Cloning: A Laboratory Manual 2nd Ed Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY

    Google Scholar 

  • Scotet E, Houssaint E . 1995 Biochem. Biophys. Acta 1264: 238–242

  • Stec I, Wright TJ, van Ommen G-JB, de Boer PAJ, van Haeringen A, Moorman AFM, Altherr MR, den Dunnen JT . 1998 Hum. Mol. Genet. 7: 1071–1082

  • Sternberg MJ, Gullick WJ . 1990 Protein Eng. 3: 245–248

  • Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin D, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ . 1995 Nature Genet. 9: 321–328

  • Thompson LM, Plummer S, Schalling M, Altherr MR, Gusella JF, Housman DE, Wasmuth JJ . 1991 Genomics 11: 1133–1142

  • Webster MK, d'Avis PY, Robertson SC, Donoghue DJ . 1996 Mol. Cell. Biol. 16: 4081–4087

  • Webster MK, Donoghue DJ . 1997a Trends in Genetics 13: 178–182

  • Webster MK, Donoghue DJ . 1997b Mol. Cell. Biol. 17: 5739–5747

Download references

Acknowledgements

Supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC) (to A Neri), the Ministero della Sanità to Ospedale Maggiore IRCCS, Milan, and from MURST 1999 no 9906038391-010.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ronchetti, D., Greco, A., Compasso, S. et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20, 3553–3562 (2001). https://doi.org/10.1038/sj.onc.1204465

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204465

Keywords

This article is cited by

Search

Quick links